Ariane Tom, PhD

Founder & Managing Director

Dr. Ariane Tom is the Founder and Managing Director of Kaleida Capital, overseeing capital allocation across brain–machine interfaces, neural data systems, and cognitive AI. A Stanford-trained neuroengineer, she began her work in 2008 designing bioelectronic interfaces for the brain, co-authoring early research with Karl Deisseroth and Zhenan Bao that helped establish the technical foundations of today’s neural-interface ecosystem. Her contributions to brain–machine interfaces, neuromodulation, and neural data systems have been featured in Science, Nature, Time, and Scientific American, and continue to inform the evolution of the neurotechnology landscape.

Following Stanford, Dr. Tom built her career across intellectual property and venture capital, developing a longitudinal understanding of how frontier technologies move from lab discovery to scaled deployment. As an Associate at Schox Patent Group, she operated in Silicon Valley patent law and technology commercialization, advising founders and investors on IP strategy, prosecution, and diligence for deep-tech and life-science startups—experience that now shapes Kaleida Capital’s emphasis on defensible infrastructure.

She later joined Anzu Partners, a leading industrial and deep-technology venture firm, where she honed a critical eye for opportunities spanning advanced materials, bioengineering, and AI-enabled life science platforms. During her tenure, she drove investment and supported the Boards of multiple Nobel Prize–winning research–derived companies and category-defining platforms, contributing to portfolio-level performance exceeding 6× MOIC.

As an independent investor, Dr. Tom subsequently built a high-performing early portfolio that includes Anthropic and Manifest Technologies (acquired by Johnson & Johnson), earning the trust of family offices, research institutions, and strategic partners seeking credible access to NeuroAI. She founded Kaleida Capital to institutionalize this edge— structuring NeuroAI exposure with discipline.

Dr. Tom holds PhD, MS, and BS degrees from Stanford University in Materials Engineering and Bioengineering. She is a member of the Milken Institute Young Leaders Circle and NVIDIA VC Alliance, and is a frequent speaker at internationally recognized forums, where she brings a global perspective on the future of intelligence—at the intersection of neural data, computation, and human performance.

    • NeuroAI Thesis & Performance | Originated and institutionalized the NeuroAI investment thesis in 2022, independently building Kaleida’s platform and closing investments to establish the category - resulting in 80% IRR and 3.3X TVPI in two years, including an exit to Johnson & Johnson within 16 months of investment. 

    • Silicon Valley IP Strategy & Technology Commercialization | Developed patent and commercialization strategies for venture-backed technology companies at Schox Patent Group—Y Combinator’s top-recommended patent firm and the firm behind foundational portfolios for companies including Twilio, Coinbase, Cruise, Joby Aviation, and Cerebras. 

    • Stanford Research Leadership | Established an early Stanford multidisciplinary neuroengineering research program in bioelectronic neural interfaces as the first PhD student jointly advised by Professor Karl Deisseroth, a pioneer of optogenetics and CLARITY, and Professor Zhenan Bao, a leader in bioelectronics. Her work advanced genetically targeted conductive polymers for neural tissue, whole-brain structural imaging, and bioinspired electronic sensing, resulting in publications in Science, Nature, and Scientific Reports. She developed expertise in neural interface engineering, biomaterials, bioelectronics, brain tissue engineering, mechanosensing, advanced microscopy, and translational neurotechnology.

    • Speaking Engagements | Frequent speaker at internationally recognized neurotech, medical device, and venture capital forums — including Biotechnology Innovation Organization (BIO) International Convention, North American Neuromodulation Society (NANS) Annual Meeting, Life Sciences Intelligence (LSI), Octane Neurotech Forum, Institute of Electrical and Electronics Engineers - Engineering in Medicine and Biology Society (IEEE EMBS) Brain Discovery Workshop, Caltech Entrepreneurs Forum, RAISE Global LP-GP Summit, Neuro Summit Lisbon, Brain Capital Innovation Summit, and Neurotech Leaders Forum.

    • Science and Policy Influence | An advisor and colleague to  scientific and policy councils shaping the global NeuroAI dialogue, including the NIH, DARPA, United Nations Science Summit, BrainMind at Asilomar, and World Economic Forum, positioning Kaleida as a trusted  institutional voice in the space.

    • Neural Interface & Bioelectronics

      • Tom, A. (2017). Integrated Locally-Synthesized and Genetically-Targeted Polymer Systems in Neural Tissue. Doctoral dissertation, Stanford University.https://purl.stanford.edu/wm962xv8083

      • Liu, J., Kim, Y. S., Richardson, C. E., Tom, A., et al. (2020). Genetically Targeted Chemical Assembly of Functional Materials in Living Cells, Tissues, and Animals. Science, 367(6484), 1372–1376.https://doi.org/10.1126/science.aay4866

    • Brain Mapping & Structural Biology

      • Chung, K., Wallace, J., Kim, S.-Y., et al., Deisseroth, K. (2013). Structural and Molecular Interrogation of Intact Biological Systems. Nature, 497(7449), 332–337.https://doi.org/10.1038/nature12107

      • Malkovskiy, A. V., Tom, A., Joubert, L.-M., et al. (2022). Visualization of the Distribution of Covalently Cross-Linked Hydrogels in CLARITY Brain–Polymer Hybrids for Different Monomer Concentrations. Scientific Reports, 12, 13549.https://doi.org/10.1038/s41598-022-17687-x

    • Prosthetic Sensing & Mechanoreception

    • Domains: Brain-Machine Interfaces, Neural Data Infrastructure, Cognitive AI, Precision Neuroscience, Neuromodulation, Materials Engineering

    • Strengths: Strategic leadership, business development, board-level Influence, public speaking, technical diligence, IP strategy, deep-tech commercialization, early-stage conviction investing

    • Networks & Memberships: Milken Institute Young Leaders Circle, NVIDIA VC Alliance, One Mind Accelerator, Stanford University (B.S. M.S., PhD, Materials Science & Bioengineering), Stanford University research community

  • All investments led by Dr. Tom on behalf of Kaleida Capital.

    • Anthropic - One of the world's leading applied AI safety companies

    • OpenAI - The defining generative AI platform globally

    • Synchron - Leader in minimally invasive, endovascular brain-computer interfaces

    • Science Corp - Neural engineering and retinal prosthetics platform founded by Max Hodak

    • Paradromics - High-data-rate neural interface technology for speech decoding and clinical BCI applications

    • Resonant Link Medical - Wireless power delivery for implantable medical devices

    • Aurenar - Wearable neuromodulation therapy designed for the ICU

    • Manifest Technologies (acquired by Johnson & Johnson) - Brain activity mapping software for neuropsychiatric clinical trials